48: We are all going to die
In which our heroes discuss the impending doom coming from Wuhan. Also wtf FDA re SRPT?
Armchair Healthcare
Share:
Listens: 194
About
Veteran healthcare analysts Max Jacobs and Nat Calloway riff on the latest news, talking about biotech as well as healthcare policy with a heavy dose of fact-based snark.
47: The amyloid hypothesis will outlive all of us.
In which we welcome our new commentator Wiktoria, and discuss the new BIIB shuck and jive.
46: The interesting Relmada data in depression and some balance sheet disasters
Discuss the recent Relmada data, Geovax, Amyris, WeWork and more
45: The hysteria around vaping and does Purdue really deserve to go bankrupt?
People need some perspective on vaping and these opioid lawsuits
44: FDA has its hands full with Novartis, Amarin and people drinking bleach
Novartis gives the FDA a headache, the FDA then gives Amarin a headache and people are trying to cure their problems with bleach
43: Interview with Thomas Meyer, CEO of Auris Medical
We discuss Auris Medical’s development programs for intranasal betahistine for acute vertigo as well as to treat some of the major side effects of ant...
42: Interview with Stephane Piat, CEO of Carmat
We discuss Carmat's total artificial heart, the technology, approval pathways and commercial potential
41: On vomit boat trials and Elon Musk
Why would anyone sign up for a vomit boat trial or get thousands of electrodes implanted into their brains?
40: Interview with Daniel Schneider, CEO of Photocure
We cover Photocure’s marketed bladder cancer diagnostic product Hexvix/Cysview, its data and potential for growth in the United States and the prospec...
39: Biotech, a magical land of mystery
Why did selinexor get approved? What's going on with Roche/Spark? Why did ITCI have crazy results? Also a farewell.